Ms. Piccina is a seasoned leader with over 25 years of experience in the pharmaceutical industry. In her role, she drives the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and is building a commercial team in anticipation of a 2025 launch.
Priorto AlloVir, Ms. Piccina served as Chief Commercial Officer of Adaptimmune Therapeutics, where she built commercialization capabilities and a team to support the launch of the company’s first commercial product, which could be the first engineered TCR T cell therapy approved for the treatment of solid tumors. Prior to this, she was the Head of Commercial and SVP Commercial Oncology at 2seventy bio and U.S. General Manager at bluebird bio, where she led the launch of the first cell therapy product in multiple myeloma, Abecma (idecabtagene vicleucel). Before this, Ms. Piccina spent more than two decades at Novartis, first in Brazil, and then in the U.S., where she held a series of commercial, marketing, and sales roles across multiple therapeutic areas including oncology, and in her final role she was VP, Global Oncology Cell and Gene Strategy & Program Management Office, for Kymriah and the CAR-T pipeline, leading the cross-functional leadership teams for business (marketing, medical affairs, market access), manufacturing, and pipeline.
Ms. Piccina holds a Doctorate in Pharmacy and Biochemistry from the University ofSao Paulo, Brazil, and an MBA from the Escola Superior de Propaganda eMarketing, Sao Paulo, Brazil.
